BB BIOTECH AG
BB BIOTECH AG: Annual report 2016 (news with additional features)
DGAP-News: BB BIOTECH AG / Key word(s): Final Results Media release as of February 17, 2017 Annual report of BB Biotech AG as of December 31, 2016 BB Biotech AG publishes its 2016 annual report BB Biotech AG published its annual report for fiscal 2016 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the biotechnology sector, BB Biotech’s positioning, the therapeutic areas covered by its portfolio and the companies it is invested in. As disclosed in the report, BB Biotech ended the year with a slightly positive total return of 0.3% in CHF and 1.9% in EUR despite the considerable difficulties the past year posed for biotech investors. Its Net Asset Value (NAV) declined by 19.1% in CHF, 17.6% in EUR and 20.6% in USD, which was somewhat better than the benchmark Nasdaq Biotech Index. The performance of BB Biotech’s shares in 2016 largely reflects the dissolution of the discount to NAV. The consolidated and audited accounts show a net loss of CHF 802 mn for fiscal 2016 compared to a net profit of CHF 653 mn in the previous year. As already announced on January 20, 2017, BB Biotech will propose an ordinary dividend of CHF 2.75 per share at the upcoming Annual General Meeting, which represents a yield of 5% based on the volume-weighted average price of BB Biotech shares in December 2016. This marks a continuation of the dividend policy as introduced in 2013. BB Biotech’s annual report 2016 can be downloaded at www.bbbiotech.com. For further information: Investor Relations Media Relations b-public AG, Pfingstweidstrasse 6, 8005 Zurich, Switzerland, Tel. +41 79 423 22 28 Company profile Disclaimer Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=EPVMJUYHCL Document title: Media release
17.02.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | BB BIOTECH AG |
Schwertstrasse 6 | |
8200 Schaffhausen | |
Switzerland | |
Phone: | +41 52 624 08 45 |
Fax: | +41 1 267 67 01 |
E-mail: | info@bbbiotech.com |
Internet: | www.bbbiotech.ch |
ISIN: | CH0038389992 |
WKN: | A0NFN3 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX |
End of News | DGAP News Service |